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Presence and frequency of rare circulating tumor cells (CTCs) in bloodstreams of cancer patients are pivotal
to early cancer detection and treatment monitoring. Here, we use a spiral microchannel with inherent
centrifugal forces for continuous, size-based separation of CTCs from blood (Dean Flow Fractionation
(DFF)) which facilitates easy couplingwith conventional downstream biological assays. Device performance
was optimized using cancer cell lines (. 85% recovery), followed by clinical validation with positive CTCs
enumeration in all samples from patients with metastatic lung cancer (n 5 20; 5–88 CTCs per mL). The
presence of CD1331 cells, a phenotypic marker characteristic of stem-like behavior in lung cancer cells was
also identified in the isolated subpopulation of CTCs. The spiral biochip identifies and addresses key
challenges of the next generation CTCs isolation assay including antibody independent isolation, high
sensitivity and throughput (3 mL/hr); and single-step retrieval of viable CTCs.
P
resence and frequency of circulating tumor cells (CTCs) in bloodstream of patients with epithelial cancers
(carcinomas) is an important intermediate step in cancer metastasis and provides valuable insights assoc-
iated with disease stage1,2 and treatment evaluations3. As compared to obtaining fresh tissue biopsy which is
often technically challenging and causes great inconvenience to patients, ‘‘liquid biopsy’’ for CTCs detection can
be carried out routinely in patients due to accessibility and ease of blood collection. More importantly, because
primary tumor sampling may not reflect the actual metastatic conditions, CTCs also serve as a representative
surrogate tumor biomarker for real-time monitoring of disease status and tailoring personalized therapy4,5.
Despite significant clinical relevance, progress on CTCs research is hindered by the lack of efficient and robust
CTCs separation techniques due to their extremely rare occurrence (,1–100 CTCs per 109 blood cells). This
coupled with their highly heterogeneous morphologies and molecular signatures makes their isolation from
blood technically challenging and limits their use as potential cancer biomarkers in clinical cancer management6.
Existing macroscale CTCs isolation/enrichment methods include density-gradient centrifugation or RBC lysis
to extract mononuclear cells, physical filtration with commercial filter pores (isolation by size of epithelial tumor
cells (ISET))7 or immunomagnetic separation against surface molecules commonly expressed on malignant
epithelial cells (most notably the commercial CellSearchH system from Veridex)8. Long processing time coupled
with laborious sample preparations often resulting in cell contamination or low CTCs recovery have hindered the
development of these techniques into an routine in vitro diagnostic test. Currently, the CellSearchH test is the only
FDA approved test for ascertaining prognosis for patients with metastatic breast, colorectal and prostate cancer.
The application of microfluidics based technologies for CTCs separation is an attractive alternative which not
only offers better control of the microenvironment during separation but also facilitates integration and auto-
mation for high throughput sample processing. Current microfluidic CTCs isolation technologies are primarily
based on physical/size based filtration9–11 or immuno-mediated CTCs capture in surface functionalized channels
or microstructures12–17. Although affinity binding methods generally provide better separation purity, the use of
surface antigens is less desirable as their expression levels are highly heterogeneous and tumor-dependent and
retrieval of captured CTCs is non-trivial due to strong cell binding in the device18. Moreover, there is a risk of
losing the most aggressive CTCs subpopulation due to epithelial-to-mesenchymal transition (EMT) which leads
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to down-regulation of epithelial markers (e.g. EpCAM) commonly
used for affinity binding and may thus underestimate the number of
actual CTCs present in the bloodstream19.
Microfluidic flows are usually associated with dominant viscous
drag forces (low Reynolds number, Re) which are responsible for
laminar flow profiles entraining suspended particles and cells along
streamlines20. Recently, we and others have shown that particles can
migrate across streamlines to focus at distinct positions in micro-
channels due to significant inertial forces (henceforth known as iner-
tial microfluidics) which can be exploited for high throughput, size-
based particle and cell separation21–24. Briefly, particle lateral migra-
tion and focusing occurs due to the superposition of two inertial lift
forces (FL) acting on the particles in opposite directions: the shear-
induced lift force and the wall-induced lift force22. In curvilinear
channels (for e.g. spiral), particles experience additional lateral
Dean drag force (FD) due to presence of transverse Dean flows arising
from the centrifugal acceleration of fluid flow in curved channels.
Interplay between inertial lift andDean forces in curvilinear channels
can be exploited for an efficient, high resolution size-based separa-
tion25,26. Although much success has been demonstrated for particles
and cell separation24,27, the use of inertial microfluidics for blood-
related separation is greatly limited by the large red blood cells
(RBCs) background (,45% v/v) whereby cell-cell interactions can
severely affect the cell focusing behavior and hence deteriorate sepa-
ration efficiency28. Typically, blood samples have to be diluted sig-
nificantly (50 2 1003) in inertial microfluidic systems, which
increases processing time to the level unsuitable to process large
volumes of clinical blood samples required for CTCs isolation
applications29.
To address these challenges, we introduce an inertial microflui-
dics-based separation technique for CTCs isolation fromblood, aptly
termed Dean Flow Fractionation (DFF). Complete separation
between a mixture of 7.32 mm and 1.9 mm polystyrene particles
has been previously demonstrated based on similar principle30. In
curvilinear channels, the influence of centrifugal acceleration in
radial direction results in the formation of two symmetrical
counter-rotating vortices (top and bottom) across the channel
cross-section31, also known as Dean vortices. Themagnitude of these
secondary flows is characterized by a non-dimensional Dean number
(De) and particles flowing in curvilinear channels experience a lateral
drag force (FD) which entrain and drive them along the direction of
flow within the Dean vortex30,32. This motion translates to the part-
icles moving back and forth along the channel width between the
inner and outer walls with increasing downstream distance when
viewed from the top or bottom. This lateral migration can be defined
in terms of ‘Dean cycle’ (DC), where a particle, which is initially
positioned near the microchannel outer wall, migrates to the inner
wall at a given distance downstream is said to have completed K
Dean cycle (DC 0.5). The same particle returning back to the original
position near the channel outer wall would complete a full Dean cycle
(DC 1). Apart from Dean drag force, larger particles and cells (par-
ticle diameter ap/h . 0.07; ap is the particle/cell diameter) in cur-
vilinear microchannels also experience appreciable inertial lift forces
(FL) near the inner wall and the resultant particle focusing position is
strongly dependent on the ratio of inertial lift to Dean drag forces
(FL/FD) which scales exponentially with particle size25,26,27.
By exploiting the size difference between CTCs and hematologic
cells (CTCs ,10–20 mm; RBC ,8 mm discoid; leukocytes ,7–
12 mm)7,33, we take advantage of these two phenomena, i.e. Dean
migration and inertial focusing, to achieve efficient CTCs separation
from blood. The microchannel design consists of a 2-inlet, 2-outlet
spiral microchannel (500 mm (w) 3 160 mm (h)) with a total length
of ,10 cm (Figure 1A). Criterion for particle focusing depends on
the shortest channel dimension (microchannel height, h)34. In our
DFF system, channel dimensions are selected such that only the
larger CTCs undergo inertial focusing, while migration of the smaller
hematologic cells (RBCs and leukocytes) is solely affected by the
Dean drag (i.e. only the CTCs satisfy the ap/h , 0.1 ratio). Blood
sample (,20% hematocrit (hct)) is pumped into the outer inlet while
sheath fluid (13 PBS) is pumped through the inner inlet at a higher
flow rate to confine the sample stream near the outer wall. As the
sample travels through the channel, all the cells (CTCs and blood
cells) initiate migration along the Dean vortex andmove towards the
inner channel. Near the inner wall, larger cancer cells or CTCs focus
tightly as they experience strong inertial lift forces, preventing them
from migrating further under the influence of Dean drag, while the
smaller blood cells continue flowing along the Dean vortex and travel
back towards the outer wall. This allows continuous collection of
CTCs at the inner outlet and blood cells (RBCs and leukocytes) are
removed from the outer outlet as waste. Since the smaller blood cells
are not focused or equilibrated in this microchannel, steric crowding
effect is eliminated which enables the processing of extremely high
hematocrit blood samples (,20%) without affecting separation per-
formance.
A key feature of DFF is the ability to continuously collect viable
CTCs allowing easy coupling with convectional 96-well plate for
subsequent biological assays. The performance of DFF was validated
using cancer cells spiked into whole blood (.85% cancer cell recov-
ery achieved), followed by preliminary clinical testing with healthy (n
5 20) and lung cancer patients (n 5 20) blood samples. Sorted cells
were enumerated using fluorescent immuno-staining to determine
recovery and subsequently cultured demonstrating high viability.
Tumor cells were successfully identified in peripheral blood of all
cancer patients (,5–88 CTCs per mL) with metastatic disease,
clearly highlighting its potential as a robust CTCs detection platform.
Unlike other affinity-capture or physical filtration microfluidic
devices, issues arising from clogging are eliminated by virtue of the
large microchannel dimensions and high flow conditions facilitating
processing of very high hematocrit blood samples. As high volume
throughput is a key requirement of any rare cell isolation technique,
the DFF operating conditions are optimized to process 3 mL whole
blood volume in an hour. To our knowledge, this is the fastest pro-
cessing speed demonstrated in microfluidics systems for continuous
CTCs isolation.
Results
Dean Cycle characterization. COMSOL simulations (COMSOL
Inc, Burlington, MA) were used to study the Dean flow profile in
the spiral device at varying Re to determine the flow rate required to
achieve a complete Dean cycle (DC 1) migration (Fig. S1). Lateral
Dean migration effect along the channel was modeled by applying
particle tracking function for fluid elements located at the outer wall
region of the inlet at DC 1 (Re,50). Corresponding positions of the
tracked streamlines were in excellent agreement with the trajectory of
3 mmbeads determined experimentally atDC 1. This was expected as
the beads (ap/h , 0.1) solely undergo Dean migration within the
channel without any influence of inertial forces (Fig. S2). To further
confirm the operational flow rates for CTCs separation, 15 mm and
6 mm fluorescent microbeads were tested individually at DC 1 to
mimic cancer cells (,15–20 mm in diameter) and RBCs (,6–
8 mm) respectively. As expected, there were distinct differences in
their flow behavior and focusing position as 6 mm beads were
successfully transposed from the outer wall towards the inner wall
and returned back to the outer wall again (similar to 3 mm beads)
while 15 mmbeads undergo strong inertial focusing (ap/h, 0.1) near
the inner wall at the channel outlet (Fig. S3).
Whole blood processing. RBCs constitute . 99% of all blood cell
components and complete RBCs removal is imperative for efficient
and meaningful isolation of rare CTCs. After corroboration of the
separation principle using fluorescent microbeads, equilibrium
positions for RBCs samples of varying hematocrit (at DC 1) were
www.nature.com/scientificreports
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used to determine the maximum sample hematocrit that the spiral
biochip can handle. Similar to 6 mm beads behavior, smaller RBCs
experienced negligible inertial forces and were found at the outer half
of the channel after a single Dean Cycle migration (Fig. 2A). As
hematocrit increased, RBCs band broadened due to cell-cell
interaction induced dispersion and a final hematocrit of 20% was
chosen as it gave ,175 mm of cell free region at the channel inner
wall with negligible RBCs recovery from the CTCs outlet (150 mm).
Compared to other inertial-based microfluidic separation methods,
20% hematocrit implies only ,23 dilution of whole blood (origi-
nal hematocrit ,40–45%). This translates to a processing time of
,20 minutes for 1 mL of whole blood after dilution (at 100 mL
min21).
While leukocytes constitute ,0.1% of all blood cells (,5 million
per mL), it is still overwhelming when compared to CTCs (,10–
100 CTCs/mL) and removal of nucleated leukocytes will signifi-
cantly reduce the background noise for subsequent molecular ana-
lysis. To study the depletion capability of leukocytes in the spiral
device, a pure population of leukocytes was obtained by RBCs lysis
and pumped through the device at DC 1. High-speed imaging (6400
frames per second) was used to capture their flow positions near the
outlet regionwhich can be represented by a linescan of the composite
image. As shown in Figure 2B, the larger leukocytes experienced
stronger drag forces during the lateral migration and do not migrate
completely back to the outer wall at DC 1. Nevertheless, the cells are
still approximately 160 mm away from the inner wall which ensures
minimal leukocytes contamination in the CTCs outlet. For this rea-
son we fixed the CTC outlet width to 150 mm.
Cell lines. Figure 2C illustrates the focusing position of MCF-7 cells
at different locations along the spiral channel. Due to the small radius
of curvature (R) in the first semi-circular spiral loop, larger cancer
cells quickly migrated laterally towards the inner wall (position 2)
due to strong Dean vortices. With increasing downstream distance,
the MCF-7 cells begin to focus tightly near the inner wall as inertial
forces have stronger dependence on particle diameter as compared to
Dean drag forces (FL / ap4 vs. FD / ap). By optimizing the width of
the CTCs outlet, high cancer cell separation efficiencies (. 85%) was
achieved which was consistent for different cell lines (Fig. 2D)25,30.
Lastly, multicellularMCF-7 clusters were also tested as CTCs clusters
have been reported in clinical samples16,35 and may yield important
prognostic significance36. Despite high flow conditions in our device,
separation and collection of intact MCF-7 clusters was successfully
achieved. This is due to the short transit time within the channel
(highest shear rates) which prevents the breakup of these cell clusters
(Fig. 2E).
DFF cascaded spiral system. To demonstrate separation of cancer
cells from blood, we spiked a high number ofMCF-7 cells (,105/mL)
into 20% hematocrit whole blood samples for testing at DC 1.
Following separation, flow cytometry analysis using common
surface markers (EpCAM and CD45) was performed on the sorted
samples to quantify CTC recovery from other hematologic cellular
components. As shown in Figure 3A, focusing positions of MCF-7
cells remained similar in PBS solution and 20% hematocrit blood
samples, clearly confirming that the presence and lateralmigration of
RBCs did not affect their inertial focusing. For complete RBCs
Figure 1 | (A) Schematic illustration of the separation principle for high-throughput CTCs isolation usingDean Flow Fractionation (DFF). Blood sample
and sheath fluid are pumped through the outer and inner inlets of the spiral device respectively. Under the influence of Dean drag forces (FD (blue
arrows)), the smaller hematologic cells (RBCs and leukocytes) migrate along theDean vortices towards the inner wall, then back to outer wall again (Dean
cycle 1), while the larger CTCs experience additional strong inertial lift forces (FL (red arrows)) and focus along the microchannel inner wall, thus
achieving separation. (B) Overall workflow of device operation and coupling with 96-well plate for various downstream applications such as CTCs
enumeration and culture of sorted CTCs.
www.nature.com/scientificreports
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removal from the sorted CTCs, a 2-stage cascaded spiral system was
set up by connecting the CTCs outlet of the first spiral device to the
sample inlet of a second spiral device (Fig. S4). This allowed subse-
quent removal of any residual RBCs and leukocytes which might
have entered the CTCs outlet (at the first stage) due to undesirable
cell-cell interactions and minimize loss of rare CTCs by eliminating
manual transfer of sorted CTCs solution to a new device (Figure 3B).
Moreover, throughput and processing time remains the same
(20 mins/mL of whole blood) as both spiral devices are operating
in conjunction with one another. Based on FACS and hemocyto-
meter analysis, a high cancer cell recovery of . 85% with enrich-
ment ratio of 109 fold (over RBCs) and ,103 fold (over leukocytes)
was achieved which is better than other size-based and affinity-based
CTC sorting techniques typically achieving 104–106 fold overall
enrichment. High cell viability (. 98%) based on Trypan blue
assay was also observed (data not shown), and is consistent with
others reporting that the high shear conditions in inertial micro-
fluidics have no adverse effects on the sorted cells27.
Besides high-throughput processing, DFF also allows continuous
collection of sorted CTCs in a single step. Downstream processing
such as CTCs enumeration or culture of sorted CTCs can now be
readily performed by lab technicians or clinicians with little training
and experience required. As an application for CTCs enumeration,
we processed 1 mL of blood samples spiked with MCF-7 cells at
physiological CTCs concentrations (,10–100/mL) followed by
immunostaining on the sorted cells. The stained cells were then re-
suspended in a 96-well plate and enumerated using an inverted epi-
fluorescence microscope equipped with a motorized stage. As shown
in Figure 3C (i), MCF-7 cells were easily distinguished from contam-
inating leukocytes based on fluorescence intensity and cell morpho-
logy. High cancer cell recovery (,85%) was achieved using small
numbers of spiked cancer cells, illustrating minimal cell loss and
the potential of our device to process clinically-relevant blood samples
(Fig. 3C (ii)). In particular, the high flow rates used in our system
prevent settling and non-specific binding of cancer cells in the syringe
and tubing, which is an important concern for enumeration of the
rare CTCs in blood. Lastly, we demonstrate successful culturing of
sorted MCF-7 cells in a 96-well plate (Figure 3C (iii)). Unlike most
microfluidic CTCs isolation systems which only allow on-chip growth
of CTCs due to difficulties in post-separation retrieval, the combined
platform of DFF and 96-well plate potentially simplifies off-chip
CTCs culture using standard cell culture techniques. Moreover, the
platform offers more flexibility on the culture substrates (culture
flasks or membrane) which can also be easily functionalized with
different ligands or extracellular matrix (Matrigel or collagen) to pro-
vide a more physiological environment for CTCs growth.
Figure 2 | Device characterization using hematological cells and cancer cell lines at Dean Cycle 1 (DC 1). (A) Averaged composite images and intensity
plot illustrate broadening RBCs occupied regions (red dashed line) for increasing hematocrit prior outlet bifurcation. Yellow dotted lines indicate
position of channel walls. (B) Linescan indicating lateral positions of leukocytes near the outlet atDC1. The larger leukocytes behaved similar to RBCs and
were transposed to outer half of the channel under the influence of Dean drag forces, resulting in minimal leukocytes entering the CTCs outlet (150 mm
width). (C) Average composite images representing the focusing position of MCF-7 cells at corresponding locations of the spiral channel. Scale bar is
1 cm. (D) Histogram plot indicating a high separation efficiency of .85% for different cancer cell lines tested. (E) Images of sorted MCF-7 clusters
stained with anti-EpCAM antibodies (red) and Hoechst dye (blue) to identify the cell membrane and nucleus respectively. Scale bar is 100 mm.
www.nature.com/scientificreports
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Clinical samples testing. After validation of the DFF cascaded sys-
tem, we processed blood samples (,6 mL volume) from 20 meta-
static lung cancer patients at various stages of treatment as an initial
clinical proof-of-concept. Blood samples from healthy individuals
were also tested as controls (n 5 20). After separation, the sample
collected from CTCs outlet was spun down and re-suspended in
100 mL and the cell suspension was transferred to a 96-well plate
for immunofluorescence staining and CTCs enumeration. Cells
were stained with Hoechst for DNA content, FITC-conjugated anti-
cytokeratin (CK) antibodies for epithelial cells and APC-conjugated
anti-CD45 antibodies for leukocytes. CTCs were enumerated based
on CK-positive (CK1), CD45-negative (CD452) and Hoechst posi-
tive (Hoechst1) while CD451 and Hoechst1 cells were identified as
leukocytes. On the basis of this classification, CTCs were successfully
detected in all cancer patients, ranging from 5 to 88 CTCs per mL
(39.1 6 24.8 CTCs/mL (mean 6 s.d.)) while 20 healthy subjects had
negligible CTCs count (0.79 6 0.42 CTCs/mL) (Fig. 4A, 4B, see
Table S1 and S2 for clinical characteristics). Leukocyte contamina-
tion was minimal with 441 6 319.5 leukocytes/mL which corre-
sponds to ,2000 fold leukocyte reduction and a much improved
CTCs/leukocytes purity of ,10% (sufficient for molecular analy-
sis). The diameter range of CTCs isolated using DFF was also
highly heterogeneous among patients (average: ,16 mm) and va-
ries from 10–22.5 mm within the same sample. Although the
ability to isolate a large size range of CTCs is favorable, the exact
mechanisms responsible for inertial focusing of smaller CTCs
(,10 mm) remain unclear and warrant further investigation. We
hypothesize that the deformability of CTCsmight have some second-
ary effects on CTCs inertial focusing. Interestingly, besides single cell
CTCs, we also observed multicellular CTCs cluster present in one of
the cancer patient blood samples (Fig. 4C). Unlike single CTCs, the
CTCs in these CTC clusters were smaller and approximately the
same size as surrounding leukocytes which is consistent with recent
report by Cho et al.37. The presence and biological significance of such
CTCs clusters in blood are still not well understood and it is debatable
whether the cells aggregate during circulation or these CTC
aggregates break away from the primary tumor as an aggregate and
circulate throughout the body35. Determining the mechanism behind
CTC aggregation is critical in understanding whether they play a role
in metastasis and is a topic of active research. In patients with
advanced lung cancer, we also stained the CTCs isolated using the
spiral biochip with CD133, a phenotypic surface marker for lung
cancer cells with higher tumorigenic potential38,39. As shown in
Fig. 4D, few isolated CTCs (CK1, Hoechst1) were stained positive
for CD133 marker, highlighting the capability of our technique to
potentially identify and isolate cancer stem cells (CSCs). These cells
play a pivotal role in cancer metastasis due to their ability to
proliferate and differentiate into multiple cell types.
Figure 3 | Isolation of cancer cells fromblood in a 2-stage cascaded spiral system. (A) Plot indicates similar focusing positions ofMCF-7 cells suspended
in PBS solution and 20%hematocrit blood samples within the pink shaded area (150 mmwide) which corresponds to the dimension of CTCs outlet. High
speed image (6400 fps) captured at the channel outlet (blue dotted box) clearly illustrates focusing of larger MCF-7 cells at the inner wall (red arrows)
while smaller RBCs occupied the outer channel region at DC 1. (B) Representative images highlighting separation of MCF-7 cells (red arrows) from 20%
hematocrit samples at different stages in the cascaded system. Plot (log scale) indicates a high cancer cell enrichment ratio of 109 fold (over RBCs) and
,800 fold (over leukocytes) using the cascaded system. (C) (i) Bright field and fluorescence images of sorted CD45-positive (green) leukocyte and
EpCAM-positive (red)MCF-7 cells on 96-well plate after immuno-staining. Both cell types were stained with Hoechst dye for nuclei identification. Scale
bar is 20 mm. (ii) High cancer cell recovery (,95%) was achieved using 96-well plate analysis after sorting blood samples spiked with physiological
relevant CTCs concentration (,10–100/mL). Inset image (red dotted box) shows a stained cancer cell (white arrow) in a well under 103 magnification.
(iii) Images showing successful culture of sorted MCF-7 cells in 96-well plate. Scale bar is 50 mm.
www.nature.com/scientificreports
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Discussion
The CTCs Grand Challenge proposed by Dr. den Toonder recently40
listed handling of large fluid volume and collection of viable CTCs
after separation as two key unresolved issues of current CTCs sepa-
ration methods. Although existing inertial microfluidics-based
devices allow high throughout processing with good separation reso-
lution, a major limitation is the use of diluted blood samples (,0.1–
2% hematocrit) which make them unsuitable to process milliliters of
clinical blood samples typically required for CTCs separation. In this
work, we introduce a high throughput blood separation technique
termed as ‘‘Dean Flow Fractionation (DFF)’’ and applied it success-
fully for CTCs isolation from blood. The use of an additional sheath
buffer in our spiral device facilitates the Dean migration of large
volume of RBCs in a well-controlled manner, thus allowing us to
process high hematocrit blood samples (,20–25%) which is demon-
strated for the first time in inertial microfluidics based systems. This
translates to a sample processing speed of ,3 mL/hr and the large
channel dimensions also eliminate clogging issues within the device,
ensuring a robust separation platform for processing of large clinical
sample volumes.
Numerous microfluidic devices for CTCs separation from blood
have been reported in recent years but few have been validated with
clinical patient samples. Nagrath et al. developed a CTC-chip con-
sisting of an array of EpCAM-coated microposts and demonstrated
99% CTC detection in 116 patients with different cancer types12.
High capture purity (,50%) was achieved in their device with a
sample flow rate of 1–2 mL/hr. The same group later developed
another microfluidic device known as the Herringbone-chip (Hb-
chip) which eliminates the use of microposts by generating micro-
vortices within the device to promote CTCs binding to EpCAM
functionalized surfaces16. Clinical validation was shown with suc-
cessful CTCs detection in 14 out of 15 (93%) patients with prostate
cancer at a higher throughput (1.5–2.5 mL/hr) and the authors also
demonstrated on-chip cell lysis, followed by RT-PCR for molecular
characterization of captured CTCs. Such EpCAM-based microflui-
dic technologies are particularly advantageous for CTCs enumera-
tion due to high capture purity and there is minimal manual
handling of these rare cells as immuno-staining and CTCs detection
are done on-chip with a small imaging area to facilitate counting.
However, these unique features also inherently limit their ability to
couple with conventional biological assays or platforms for other
downstream applications (such as CTCs growth or high-throughput
drug screening) as retrieval of captured CTCs would be difficult due
to strong cell binding to the functionalized substrates. In this aspect,
DFF is a more versatile and convenient separation technique as it
allows a continuous collection of sorted CTCs in a single step which
can be further processed for applications beyond enumeration.
A growing amount of evidence has shown that subpopulation of
carcinoma cells at the primary tumor undergo EMT, resulting in
their increased motility which facilitates their intravasation into
the blood circulation to form CTCs41. More recently, EMT has been
associated with stem-like phenotype42,43 and this subpopulation of
cancer cells, also known as cancer stem cells (CSCs) or tumor ini-
tiating cells, are the most resistant to chemotherapy and thus
regarded highly important for personalized medicine research44. As
EMT leads to down-regulation of epithelial markers (e.g. EpCAM)
commonly used for CTCs capture in affinity-basedmethods, systems
such as CellSearchH may tend to isolate lower number of CTCs,
missing cells that have undergone complete EMT phenotype or have
low level of cytokeratin expression45,46. Moreover, clinical studies
have shown that some CTCs isolated from peripheral blood also
express EMT and stem cell markers47,48, which further advocates
the importance of using non-EpCAM enrichment methods and
additional EMTmarkers such as vimentin andN-cadherin for accur-
ate CTCs enumeration. We successfully showed the existence of
CD1331 cells in the isolated subpopulation of CTCs in clinical sam-
ples from advancedmetastatic lung cancer patients. CD133, a surface
glycoprotein which has been shown to overexpress in highly tumori-
genic cells is a popular phenotypic marker for lung cancer cells with
stem-like behavior38,39. Significant numbers of CK2/CD452/Hoe-
chst1 cells were also collected from the spiral biochip (data not pre-
sented) and further molecular testing and sequencing of these rare
CTCs subtype and unknown cell population is necessary to deter-
mine their origin and their role in cancer metastasis. Although our
spiral biochip has the ability to isolate a large heterogeneity of CTC
size including CTCs which have overlapping sizes with the leuko-
cytes, the minimum CTC size cutoff is ,11 mm (ap/h ,0.07) and
CTCs smaller than 10 mm are inevitably lost in the waste outlet. This
affects the accuracy of the CTCs enumeration but our size-based
separation approach would also provide a larger CTCs pool (inde-
pendent of EpCAM expression) for identification of CTCs subpo-
pulation or EMT-derived CTCs. In addition, CTCs microemboli as
large as 50–100 mm were also successfully isolated in some cancer
patients and the continuous collectionmode of our technique poten-
tially allows further molecular studies on these rare cell clusters to
gain valuable insights related to cancer metastasis.
Figure 4 | Enumeration of CTCs from cancer patients. (A) Summary of
CTCs count per mL of blood for healthy samples and patients with
metastatic lung cancer. (B) CTCs enumeration plot for healthy donors
(red) and lung cancer patients (blue). Dashed line indicates threshold of
5 CTCs/mL. (Inset) Representative image (603 magnification) of isolated
CTCs and leukocytes from lung cancer patients stained with antibodies
against cytokeratin (green), CD45 (red) and Hoechst (blue). CTC
morphology is characterized by high nuclear: cytoplasmic ratios. Scale bar
is 20 mm. (c ) Optical images (603 magnification) of an isolated CTC
microcluster using DFF. Scale bar is 50 mm. (D) Bright field and
fluorescence images (603 magnification) of sorted CTCs stained for stem
cell marker CD133 (red), cytokeratin (green) andHoechst (blue). Scale bar
is 20 mm.
www.nature.com/scientificreports
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Isolation of these rare CTC is only the first step towards a more
comprehensive study and analysis of the role of these cells in the
spread of cancer. To this end, we believe the DFF technique offers
several distinct advantages over other microfluidic CTCs separation
methods. Firstly, the device can process 3 mL of whole blood in an
hour with 100% CTCs detection in all cancer patients, offering
unprecedented throughput and separation performance. Unlike
affinity-capture or physical filtration microdevices, the continuous
collection of sorted CTCs and short residence time in the device
(,10 msec) significantly shortens the CTCs exposure time to con-
stant shear in the channel, thus minimizing any undesirable shear-
induced changes to the CTCs phenotype. This is important because
retrieval of isolated CTCs for subsequent molecular characterization
of biological functions or gene expression for targeted drug therapy is
the hallmark of personalized medicine. Lastly, sample preparation is
minimal and only syringe pumps are required which simplifies the
device setup and operation. This is a key consideration for successful
commercialization and implementation in clinical settings as tech-
nicians and clinicians can readily run the biochip with little training
and experience required. We envision that with all these aforemen-
tioned advantages, DFF would be a versatile blood separation tech-
nique which can be applied for other diseased cell separations from
blood characterized by differences in cell morphology.
Methods
Device fabrication. The microfluidic devices were fabricated in
polydimethylsiloxane (PDMS) using standard microfabrication soft-lithographic
techniques described previously49. Briefly, the patterned silicon wafers were silanized
with trichloro (1H,1H,2H,2H-perfluorooctyl) silane (SigmaAldrich, USA and PDMS
prepolymer mixed in 1051 (w/w) ratio with curing agent was poured onto the
silanized wafer and baked at 80uC for 1–2 hrs. The cured PDMS mold was then used
as a template (negative replica) for subsequent PDMS casting which gave the final
PDMS microchannels. Holes (1.5 mm) for fluidic inlets and outlets were punched
and the PDMS devices were irreversibly bonded to microscopic glass slides using an
air plasma machine (Harrick Plasma Cleaner, USA).
COMSOL modeling. Commercially available COMSOL Multiphysics (COMSOL
Inc, Burlington, MA) software was used to study fluid flow behavior in the proposed
spiral design. The model structure consists of an inner semi-circular channel with
radius R1 5 0.42 cm and a spiral channel R2 5 (1.0 1 0.1h/2p) cm. Width (w) and
height (h) of the channel were fixed at 500 mm and 155 mm respectively. Full Navier-
Stokes equations for incompressible fluids were solved using finite element method.
For simplicity, it was assumed that the presence of suspended particles does not affect
the intrinsic properties of the fluid (a continuum fluid with density 1 g cm23 and
dynamic viscosity 0.001 Pa s). Fluid flowwith varying flow rates (inmL/min) and no-
slip boundary conditions were applied at the channel inlet and channel wall
boundaries respectively. At the outlet, the pressure was set to zero with no viscous
stress on the boundary. As the flow is symmetric about the middle plane in the z
direction (depth), only half of the channel (upper channel) was modeled (Figure S1),
which introduced an additional symmetric boundary condition for that symmetric
plane. From the steady-state solution for single-phase laminar flow, Dean migration
of the fluid elements (similar as particles) at the outer wall region were obtained using
particle tracking functionality in the software and compared with experimental
observations of fluorescence microbeads lateral migration. For calculation of Dean
flow, a separate semi-circular channel with the same dimensions as the spiral channel
was modeled under similar fluid flow conditions. The radius of the channel was set as
0.42 cm and 1.0 cm respectively, which corresponds to inner and outer loop of the
spiral channel. Maximum Dean and axial flow speed were then calculated at mid
point along the circular channel at different flow rates, where the error caused by the
boundary effect is expected to be negligible.
Cell culture. Human breast adenocarcinoma cell lines, MCF-7 and MDA-MB-231,
and human cervical HeLa cell line were used to mimic CTCs separation in this work.
The cells were cultured in low-glucose Dulbecco’smodified Eagle’smedium (DMEM)
(Invitrogen, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen,
USA) together with 1% penicillin/streptomycin (Invitrogen, USA). The culture was
maintained at 37uC in a humidified atmosphere containing 5% (v/v) CO2. The cells
were sub-cultivated every 4 days with media replaced every 48 hours. Sub-confluent
monolayers were dissociated using 0.01% trypsin and 5.3 mM EDTA solution
(Lonza, Switzerland).
Sample preparation. Fluorescently labeled microbeads of 6 and 15 mm diameter
(FluoresbriteHMicrospheres, Polysciences Inc, Singapore) were added (0.01%
volume fraction) to sample buffer which consists of 13 phosphate buffered saline
(PBS), 2 mM ethylenediaminetetraacetic acid (EDTA) supplemented with 0.5%
bovine serum albumin (BSA) (Miltenyi Biotec, Germany). BSA was used to prevent
non-specific adsorption to the tubing and microchannel walls. For RBC hematocrit
experiments, whole blood obtained from healthy donors was spun down to separate
the RBCs. Final sample concentration was adjusted to varying hematocrit (1%–45%)
with sample buffer accordingly. For leukocyte control experiments, whole blood was
treated with RBC lysis buffer (eBioscience, USA) according to the manufacturer’s
instructions to obtain a pure population of leukocytes. To study the focusing of cancer
cells in spiral channel, a high concentration of cancer cells (,105 cells/mL) were
added into the sample buffer to facilitate high speed imaging and analysis. Whole
blood experiments were carried out by diluting fresh blood samples to ,20%
hematocrit spiked with MCF-7 cells (,105/mL). .100 000 events of cells for flow
cytometry (FACS) analysis were recorded for greater accuracy of data obtained.
Device characterization.During testing, cancer cell and blood sample was filled in a
1 mL syringe and pumped through the spiral microfluidic device using a syringe
pump (NE-1000, New Era Pump Systems Inc., USA) while sheath flow (13 PBS,
2 mM EDTA supplemented with 0.5% BSA) was filled in a 60 mL syringe and
pumped into the device using a separate syringe pump (PHD 2000, Harvard
Apparatus, USA). The flow rate ratio between the sample and sheath flow was fixed at
15 9 to form a tight sample stream at the outer wall. The devices were mounted on an
inverted phase contrast microscope (Olympus IX71) equipped with a high speed
CCD camera (Phantom v9, Vision Research Inc., USA). High speed videos were
captured at the channel outlet using Phantom Camera Control software and then
analyzed using ImageJH software. For fluorescence imaging, another inverted
microscope (Olympus IX81, Olympus Inc., USA) equipped with a 12-bit EMCCD
camera (iXonEM 1 885, Andor Technology, USA) was used. Images were acquired
using MetamorphH software (Molecular Devices, USA) and analyzed using ImageJH
software.
Immunofluorescence staining and FACS analysis. To determine the enrichment
ratio between the sample and sorted CTCs, flow cytometry (FACS) analysis using
BDTM LSR II flow cytometer (BD Biosciences, USA) was performed on the inlet and
CTC outlet samples. Immunofluorescence staining allowed differentiating the
various cell types for visualization and quantification. After sorting, the cells were
stained with allophycocyanin (APC) conjugated Epithelial Cell Adhesion Molecule
(EpCAM) (15100, Miltenyi Biotec Asia Pacific, Singapore) and fluorescein
isothiocyanate (FITC) conjugated CD45marker (15100, Miltenyi Biotec Asia Pacific,
Singapore) for 30 minutes to identify MCF-7 cells and blood leukocytes respectively.
RBCs concentration was further confirmed using hemocytometer measurement.
For clinical samples, cells isolated from the spiral biochip were fixed and per-
meabilized using the Inside Stain Kit (MiltenyiBiotec Asia Pacific, Singapore)
according to the manufacturer’s protocol. CTCs were identified by staining with
FITC-conjugated pan-cytokeratin (CK) (15100, MiltenyiBiotec Asia Pacific,
Singapore) for 30 minutes at 4uC and washed twice with 13 PBS before imaging.
Cells staining positive for pan-CK and Hoechst (nuclei stain) and negative for CD45
with characteristic morphology of cancer cells (i.e., high nucleus to cytoplasm ratio)
are identified as CTCs. Cells staining positively for CD45 and Hoechst and negatively
for pan-cytokeratin are identified as leukocytes. APC-conjugated CD133 (15100,
MiltenyiBiotec Asia Pacific, Singapore) was also used for tumor subtype identification
in patients with advanced lung cancer.
Sample preparation and clinical testing of study subjects. Blood samples were
obtained from healthy volunteers and metastatic lung cancer patients with informed
consent. The clinical sample collection protocols were reviewed and approved by the
Domain Specific Review Boards of the National University Health System, Singapore,
National University of Singapore and the Singapore Health Services (SingHealth). A
total of 20 blood samples from healthy volunteers were used as controls and 20
samples from lung cancer patients were processed for CTC enumeration. Clinico-
pathologic information was recorded for all patients. All blood specimens were
collected in EDTA-contained vacutainer tubes (BD, Franklin Lakes, NJ, USA) and
diluted 152 (1X) with PBS buffer prior to processing on chip. The CTC capture from
actual cancer patient samples was performed in a similar procedure to that described
above. An average of 6 mL blood volume was processed for lung cancer patient
samples while 3 mL blood volume was processed from healthy volunteers as control
(Supplementary Table 1 and 2).
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